Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Abstract

BACKGROUND:

Up to 3 years of treatment with alendronate, 5 mg/d, prevents postmenopausal bone loss.

OBJECTIVE:

To determine whether the effect of alendronate is sustained at 4 years of treatment and persists after treatment is discontinued.

DESIGN:

Randomized, controlled trial.

SETTING:

United States and Europe.

PARTICIPANTS:

1609 postmenopausal women 45 to 59 years of age.

INTERVENTION:

Participants were randomly assigned to receive oral alendronate, 5 mg/d or 2.5 mg/d; placebo; or open-label estrogen-progestin. Women in the alendronate groups received alendronate for the first 2 years of the study. Treatment was then continued without change or replaced with placebo for the last 2 years of the study.

MEASUREMENTS:

Annual measurement of bone mineral density.

RESULTS:

By year 4, the bone mineral density of participants in the placebo group had decreased by 1% to 6% (P < 0.001). Four years of treatment with 5 mg of alendronate per day increased bone mineral density at the spine (mean change [+/-SE], 3.8%+/-0.3%), hip (mean, 2.9%+/-0.2%), and total body (mean, 0.9%+/-0.2%) (P < 0.001 overall). By year 4, bone mineral density at most skeletal sites was greater in participants who switched from alendronate to placebo than in those who continuously received placebo. In years 3 and 4, bone loss in participants who switched from alendronate to placebo was similar to that seen during years 1 and 2 in those who continuously received placebo. Compared with 5 mg of alendronate per day, estrogen-medroxyprogesterone acetate produced similar increases in bone mineral density and estradiol-norethisterone acetate produced increases that were substantially greater.

CONCLUSIONS:

Four years of treatment with alendronate or estrogen-progestin prevented postmenopausal bone loss. A residual effect was seen 2 years after alendronate therapy was stopped; however, continuous alendronate treatment was more effective in preventing postmenopausal bone loss than 2 years of alendronate followed by 2 years of placebo.

• Authors: P Ravn, M Bidstrup, R D Wasnich, J W Davis, M R McClung, A Balske, C Coupland, O Sahota, A Kaur, M Daley, G Cizza
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 131 Issue 12 Pg. 935-42 (Dec 21 1999) ISSN: 0003-4819 [Print] United States
• PMID: 10610644 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Estrogens
• Progestins
• Alendronate

Topics

• Alendronate (adverse effects, therapeutic use)
• Bone Density (drug effects)
• Data Interpretation, Statistical
• Double-Blind Method
• Drug Therapy, Combination
• Estrogens (adverse effects, therapeutic use)
• Female
• Humans
• Middle Aged
• Osteoporosis, Postmenopausal (prevention & control)
• Progestins (adverse effects, therapeutic use)